Public Profile

Antengene

Antengene Corporation Limited, headquartered in China, is a pioneering biopharmaceutical company focused on the development and commercialisation of innovative therapies for cancer treatment. Founded in 2017, Antengene has rapidly established itself in the oncology sector, with a strong emphasis on precision medicine and targeted therapies. The company operates primarily in Asia-Pacific regions, aiming to address unmet medical needs through its robust pipeline of novel drug candidates. Antengene's core products include a range of innovative therapies that leverage cutting-edge technology, setting them apart in a competitive market. With notable achievements in clinical trials and strategic partnerships, Antengene is positioned as a key player in the biopharmaceutical industry, committed to improving patient outcomes and advancing cancer care globally.

DitchCarbon Score

How does Antengene's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

25

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

33

Industry Benchmark

Antengene's score of 25 is lower than 63% of the industry. This can give you a sense of how well the company is doing compared to its peers.

37%

Let us know if this data was useful to you

Antengene's reported carbon emissions

In 2023, Antengene reported total carbon emissions of approximately 1,169,980 kg CO2e, with Scope 1 emissions at about 45,220 kg CO2e and Scope 2 emissions at approximately 1,124,760 kg CO2e. This represents a decrease from 2022, where total emissions were about 1,613,260 kg CO2e, with Scope 1 emissions of approximately 551,320 kg CO2e and Scope 2 emissions of about 1,061,940 kg CO2e. The company has disclosed emissions data for Scope 1 and Scope 2 but has not provided information on Scope 3 emissions. Antengene has not set specific reduction targets or initiatives as part of its climate commitments, indicating a potential area for future development in their sustainability strategy. Overall, Antengene's emissions data reflects a commitment to transparency, although further action may be needed to establish concrete reduction goals and enhance their climate strategy.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

2020202120222023
Scope 1
27,080
00,000
000,000
00,000
Scope 2
251,390
000,000
0,000,000
0,000,000
Scope 3
-
-
-
-

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Antengene's primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Antengene is in CN, which we do not have grid emissions data for.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Antengene is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

Astra Zeneca

GB
Pharmaceutical Preparation Manufacturing
Updated about 3 hours ago

Schrodinger

US
Computer and related services (72)
Updated about 3 hours ago

MERCK Kommanditgesellschaft auf Aktien

DE
Pharmaceutical Preparation Manufacturing
Updated about 3 hours ago

Debio Recherche Pharmaceutique S.A.

CH
Pharmaceutical Preparation Manufacturing
Updated 7 days ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers